US, AstraZeneca strike deal for COVID-19 antibody that was used in Trump's treatment
The agreement, under the Trump administration`s Operation Warp Speed, is for developing a monoclonal antibody cocktail that can prevent COVID-19, especially in high-risk population, like those over 80 years old, the US Department of Health and Human Services said.
Regeneron signed a $450 million deal in July to sell Operation Warp Speed enough doses of its antibody treatment, REGN-COV2, to treat around 300,000 people. Photo: Reuters